Background Increased plasma cell infiltration in renal allograft biopsies is a rare finding associated with poor outcome in adult renal transplant recipients. The clinical impact of increased plasma cell infiltrates in paediatric renal transplant recipients (pRTR) remains unknown. Methods We conducted a retrospective case-control study from April 1996 to March 2014 comparing the outcome of pRTR with increased (>10 % of infiltrate) plasma cells in renal transplant biopsies to a control cohort of pRTR without increased plasma cell infiltration but similar grade of rejection according to Banff classification. Results Increased plasma cell infiltrates were present in 14 of 162 (9 %) reviewed pRTR aged 3.2-17.5 (median 13.4) years at time of transplantation. Compared with 14 pRTR renal transplant biopsies without significantly increased plasma cells, there were no significant differences in mismatch and baseline estimated glomerular filtration rate (eGFR). Plasma cells were present in case biopsies at a maximal density of 14-116 (median 33) plasma cells/HPF. Increased plasma cells were associated with decreased eGFR at biopsy (22 vs. 49 ml/min/1.73 m 2 ; p < 0.001) and 4 weeks post-biopsy (26 vs. 56 ml/min/1.73 m 2 ; p < 0.001) despite comparable eGFR 4 weeks prior to biopsy. Increased plasma cells were further associated with significantly increased frequency of renal allograft loss (71 % vs. 7 %; p < 0.001) at 0-27 (median 2) months after biopsy. Conclusion Increased plasma cell infiltrates in pRTR are uncommon but associated with significantly reduced renal allograft survival as well as significantly reduced allograft function in surviving grafts.
Introduction
Treatment and outcome of renal allograft acute rejection (AR) episodes in adults and children are mainly determined by the histopathological findings according to revised Banff classifications [1] . Acute cellular rejection episodes are classified according to three main criteria: vasculitis/endothelialitis, tubulitis and interstitial infiltration [1] . Interstitial infiltrates are mainly composed of T lymphocytes, monocytes and macrophages. Typically, plasma cells account for <5 % of infiltrating cells in AR episodes [2] . During the last decade, episodes of plasma-cell-rich AR (PCAR) have been reported, referring to AR episodes in which plasma cells are increased to >10 % of the graft infiltrating cells. To date, PCAR has been observed in ∼2 % of adults with biopsy-proven AR [2, 3] and has been reported to be associated with poor prognosis compared with standard AR with equivalent Banff scoring [4, 5] .
The frequency and prognostic significance of plasma-cell-rich AR in paediatric renal transplant recipients (pRTR) remains unknown and has not yet been studied. We therefore conducted a retrospective case-control study of pRTR with acute or chronic rejection episodes and compared them with plasmacell-rich infiltrates with standard rejection without increased plasma cells but equivalent Banff scoring.
Materials and methods
Patients underwent percutaneous renal transplant biopsy for renal allograft dysfunction as demonstrated by acute rise in plasma creatinine ≥10 % from baseline or chronic renal allograft dysfunction with slowly rising creatinine. Cases were defined as pRTR who underwent a renal allograft biopsy for acute, chronic or acute-on-chronic allograft dysfunction from April 1996 to March 2014 and who were found to have increased plasma cell infiltration noted on the transplant biopsy (indicating plasma cells >10 % of the graft infiltrating cells).
Cases were compared with a control cohort of pRTR who also underwent renal allograft biopsy for the same indications during the same time period at the same centre who were without increased plasma cell infiltration. Controls do not reflect matched pairs but do not differ significantly from cases in the following criteria: year of renal transplantation, patient age at renal transplantation, type of transplant, patient age and transplant age at biopsy, and biopsy scoring according to Banff classification. The outcome during control selection was unknown. Data obtained additionally to those criteria included the following: sex, primary diagnosis, number of transplants, mismatch, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) of recipient and donor at time of transplantation, renal biopsy findings and presence of donor-specific antibodies. Plasma creatinine and estimated glomerular filtration rate (eGFR) using the Schwartz formula were collected for following time points in regards to the biopsy date: baseline (lowest creatinine reached posttransplantation), 3 months prior, 4 weeks prior, date of biopsy and 4 weeks post-biopsy. Data on outcome at final follow-up were collected. Renal allograft loss was defined as the requirement for renal replacement therapy (RRT) with dialysis and/or retransplantation.
The revised Banff 2007 working classification of renal allograft pathology was used to define AR and chronic changes [1] . AR was graded as I, II, III or borderline Bsuspicious^for AR, with grade I AR referring to the histological finding of interstitial lymphocytic infiltration and tubulitis, grade II AR with endothelialitis, grade III AR with transmural arteritis and/or arterial fibrinoid change and borderline BsuspiciousÂ R to foci of mild tubulitis only. Chronic changes of interstitial fibrosis, tubular atrophy, chronic large-vessel changes and arteriolar hyalinosis were noted. Cases with subjectively increased plasma cell infiltration were identified from the records, and controls reported with similar Banff severity were identified. All biopsies were then reviewed blindly, and maximal plasma cell counts per high power field (×40 objective) in the most affected areas were derived. Plasma cells were rare in the controls, whereas in cases, numerous plasma cells were present, consistent with the previously suggested criteria of >10 % of infiltrating inflammatory cells in the region.
Immunosuppression protocol
Patients in receipt of their first transplant with no history of cytotoxic antibodies received triple immunosuppressive therapy with corticosteroids [with prednisolone (P)], azathioprine (A) or mycophenolate mofetil (MMF) and tacrolimus (T) or ciclosporin (C) in the historical cohort as their baseline immunosuppression. There was one patient in the control cohort who received a second deceased-donor allograft. This patient received quadruple immunosuppressive therapy including the above triple therapy and additional treatment with basiliximab. Historically, patients with biopsy-proven chronic allograft nephropathy (CAN) had azathioprine switched to MMF, and the calcineurin inhibitor withdrawn or reduced.
Statistics
All statistics were performed using SPSS version 22 (IBM). Kaplan-Meier survival curves were used to examine renal allograft survival for those with and without plasma cell infiltrates. Other relevant clinical and laboratory data were compared between cases and control cohort using the Mann-Whitney U test or the Fishers exact test with significance set at p < 0.05. The log-rank test was used for significance testing for the Kaplan-Meier plots of renal allograft survival. Chi-square statistics was used for comparisons of binary data.
Results

General demographics of cases and controls
Increased plasma cell infiltrates were present in renal transplant biopsies studied from 14 of 162 (9 %) pRTR who underwent renal transplant biopsies for investigation of acute or chronic allograft dysfunction. Those with increased plasma cells were eight boys (57 %), median age 13.4 (3.2-17.5) years at time of transplantation, of whom 13 (93 %) received deceased-donor renal transplants and had received their first transplant. The control cohort of 14 RTR without increased plasma cells in renal transplant biopsies were eight boys (57 %), median age 12.2 (3.2-16.6) years at time of transplantation, of whom nine (64 %) received deceaseddonor renal transplants and one was retransplanted. The primary pathologies of both groups were typical of paediatric end-stage kidney failure and are summarised in Table 1 .
There were no significant differences between cases and controls in age at transplant, sex, type of transplant [living related donor (LRD) vs. deceased donor (DD)], mismatch, EBV/CMV status of recipient at transplant and patient, transplant age at biopsy and baseline eGFR in ml/min/1.73 m 2 ( Table 2) .
Immunosuppression
Baseline immunosuppression in cases consisted of prednisolone, azathioprine, and tacrolimus (PAT; n = 9) or prednisolone, MMF, tacrolimus (PMT; n = 2) or prednisolone, azathioprine, ciclosporin (PAC; n = 2) and prednisolone, tacrolimus, rituximab (PTR) in one patient who had a previous heart and lung transplantation with posttransplant lymphoproliferative disorder (PTLD). In controls, baseline immunosuppression was PAT (n = 9) or PMT (n = 1) or PAC (n = 1) or PMT with basiliximab IV (n = 1) or PMT with daclizumab IV (n = 1) or PAT with basiliximab IV in the one patient who received a second transplant. Historically, the initial tacrolimus target trough levels are 15 mcg/l (10-20 mcg/l) for the first 3 weeks posttransplant then 10 mcg/l (5-15 mcg/l) for days 22-183 and then wean according to patient response to 5-8 mcg/l. There were no documented cases of nonadherence.
Plasma cells and biopsy findings
Median age of cases at biopsy was 15.9 (4.8-17.9) years, with a median transplant age of 18.6 (4.9-106.5) months compared with median age at biopsy of 13.5 (5.6-17.6) years and median transplant age of 8.7 (0.7-103.2) months for controls (p = 0.21 and p = 0.14, respectively). There was no significant difference in number and grade of rejection according to Banff classification between cases and controls. In the group with increased plasma cells, one patient had findings of tubulointerstitial nephritis, which could not be classified within the Banff criteria (Table 3 ). There was no evidence of chronic humoral rejection in the plasma-cell-positive patients. Plasma cells were present in cases with a median maximal density of 32.5 (range 14-116) plasma cells/HPF. In control biopsies, plasma cells were found in ten patients, with a median of two (range 0-5) plasma cells/HPF (Fig. 1) .
Donor-specific antibodies were measured in patients and controls at the time of biopsy. Donor-specific antibodies were present in six (43 %) cases (57 % class I, 29 % class II and 14 % class I and II HLA antibodies) with total MFI of 1252-7709. Donor specific antibodies were present in 5 (36 %) controls (40 % class I, 40 % class II and 20 % class I and II HLA antibodies). Patients and controls were treated with augmented immunosuppression according to their biopsy results and according to the respective guidelines in our hospital. As all patients were treated in the same hospital, the treatment regimen for cases and controls was the same. Within the patient cohort, four were treated with methylprednisolone IV after diagnosis of PCAR, one patient additionally with rituximab IV and one with plasma exchange.
Plasma cells and renal allograft function
There was no significant difference in mean eGFR at baseline [75.9; standard deviation (SD) ± 19.9 vs. 88.2; SD ± 26.7 ml/min/ ; whereas that of controls improved to 55.7 (SD ± 14.1) ml/min/1.73 m 2 (p < 0.001) (Fig. 2) .
Plasma cells and outcome
Patients with increased plasma cells had an increased rate of renal allograft failure, with return to dialysis and/or retransplantation in ten (71 %) patients with increased plasma cells vs. one (7 %) with no increase (p < 0.001; Fig. 3 ). One patient returned to peritoneal dialysis (PD), eight to haemodialysis (HD) and two (including the one from the control group) were retransplanted.
The time to renal allograft failure was 5-95 (median 24) months post-transplantation and 0-27 (median 2) months post-biopsy in the increased plasma cell group vs. 53 months post-transplantation and 14 months post-biopsy in the patient without increased plasma cells (Table 2) Acute rejection-I a 3 3
Acute rejection-I b 2 1 Acute rejection-II a 3 3
Acute rejection-II b 1 1 Chronic changes 1 3
Other 1 (13/14) for cases and 100 % for controls. Death occurred in one case at 3.9 years post-transplantation and 3.5 years post-biopsy due to severe sepsis. The patient had a functioning allograft at time of death.
Discussion
This is the first study investigating the frequency and outcome of increased plasma cell infiltrates in paediatric patients with renal allograft biopsies. We demonstrated that this complicates ∼10 % of paediatric RTR undergoing an indication biopsy of their allograft and is associated with a significantly increased risk of renal allograft loss. Plasma-cell-rich AR is a relatively newly described entity characterized by the presence of prominent plasma cells as part of the interstitial inflammatory infiltrate. These findings are rare but have been reported with a frequency of 2-14 % of adult cases with biopsy-proven AR [2] [4] [6] [7] . There are very few case reports of PCAR in pRTR [8] . We therefore studied pRTR who underwent an allograft biopsy for acute, chronic or acuteon-chronic allograft dysfunction and report a prevalence of 9 %, which is similar to results reported in the adult population.
Due to the low prevalence of PCAR, it is difficult to define possible risk factors. We identified no significant preceding or concurrent events at the time of biopsy that differed from cases to controls. In particular, there were no significant differences in baseline immunological criteria (type of transplant and number of HLA mismatches). In cases, more patients were EBV positive at time of transplantation, but this was not a significant difference. Plasma cell infiltrates have been reported in association with EBV-induced PTLD [9] [3], and Suzuki et al. discussed whether PCAR may be an atypical form of PTLD (polymorphic PTLD or plasmacytoma-like PTLD) [10] . However, none of our patients with plasma cell infiltrates developed PTLD subsequently. Furthermore, plasma-cell-rich cases were not atypical and showed no other features of PTLD. No other clinical parameter, including age or age of transplant at time of biopsy, were significantly different between groups. In adult studies, similar findings are reported [2] [5] [11] .
In our paediatric cohort we observed that at the time of biopsy, patients with PCAR already had significantly reduced eGFR (mean 22.3 vs. 48.8 ml/min/1.73 m 2 , p < 0.001) compared with controls. Both groups received standard treatment for rejection according to Banff classification. Four weeks postbiopsy, controls with AR showed an increase in mean eGFR to 55.6 ml/min/1.73 m 2 , whereas that of cases remained significantly lower, at 25.7 ml/min/1.73 m 2 (p < 0.001). These findings confirm previously reported observations of poor PCAR response to augmented immunosuppression in the adult population [11] [12] .
The clinical significance and impact on renal allograft survival has only been addressed in adult studies and remains uncertain [2] [4] [5] [7] . In one study of 16 patients with PCAR and 17 controls, there was no significant difference in the proportion of grafts lost by 1 and 3 years of follow-up (50 % vs. 59 % and 63 % vs. 76 %, p = 0.2) or median time from biopsy to graft loss (4.5 vs. 6 months) between patients with PCAR and controls [4] . In contrast, most other studies reported poorer renal allograft outcome and shorter time to renal allograft loss in PCAR [2] [5]. For example, Charney et al. reported renal allograft loss of 52 % in PCAR vs. 20 % (p < 0.05) in AR, with a mean of 6.3 vs. 21.5 months post-biopsy [5] . Similar findings with significantly more adverse prognosis in the plasma-cell-rich group compared with those with nonrich plasma cells are described elsewhere [7] .
In our population, renal allograft loss occurred in ten (71 %) patients with plasma cell infiltrates compared with only in one (7.1 %) patient without plasma cells (p < 0.001). Renal allograft loss also occurred significantly earlier post-biopsy in cases compared with controls (median 2 months vs. 14 months in one control patient). Furthermore, patients with PCAR were more likely to develop more severe chronic allograft changes with lower eGFRs at final follow-up. Similar findings are reported in adults, with plasma creatinine remaining high in four of five patients with PCAR and surviving graft in one study [11] . Overall, data from the adult population and our current data strongly suggest that PCAR is associated with significantly worse outcome, independent of the severity of rejection, according to other standard Banff criteria. There are limitations to this study, as it was retrospective.
In the future, bortezomib, a proteasome inhibitor that induces apoptosis in mature plasma cells, may play a role in managing such patients, although none of our patients in this cohort were treated with it. Bortezomib has approval for treatment of relapsing multiple myeloma and mantle cell lymphoma and is used in the management of acute and Fig. 3 Kaplan-Meier renal allograft survival curve after biopsy for patients with (cases) and without (controls) increased plasma cells in renal transplant biopsies chronic antibody-mediated rejection as well as some adult renal and liver transplant recipients [13] . However, side effects are reported, and further investigation is necessary in the paediatric population [14] .
In conclusion, our findings demonstrate that the presence of plasma-cell-rich infiltrates in paediatric renal transplant biopsies is associated with reduced renal allograft survival and function in surviving grafts. National and international collaborative studies are required to investigate the incidence and significance of plasma cell infiltrates in paediatric renal transplant biopsies. In the future, targeted therapies in such cases may play a role in patient management.
